Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principal investigator, Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) to have a deep dive into the practice-changing CLEAR-Outcomes trial ().

The Phase III CLEAR-Outcomes trial was conducted to evaluate the impact of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with cardiovascular disease or those at high risk of developing it who are statin intolerant. During the study 13,970 patients were randomised at 1250 sites in 32 countries.
The findings, presented at ACC Scientific Sessions, showed that bempedoic acid is an effective approach to reduce major cardiovascular events in statin intolerant patients: The primary endpoint, 4-component MACE was reduced 13% in patients who either high risk primary for primary prevention and for secondary prevention.

Recorded remotely from Hamilton and Cleveland, 2023.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter:

Чтобы скачать видео "ACC 23 Late-Breaker Discussion: The CLEAR-Outcomes Trial" передвинте ползунок вправо